On the public citation graph

Medications for Opioid Use Disorder Save Lives

https://doi.org/10.17226/25310
0 signed · 712 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3696511openalex-extracted
Policing Opioid Use Disorder in a Pandemic
inferred← citeshttps://doi.org/10.2139/ssrn.4093881openalex-extracted
inferred← citeshttps://doi.org/10.2139/ssrn.4188937openalex-extracted
Higher Buprenorphine Dose Associated with Increased Treatment Retention at Mobile Buprenorphine Clinic: A Retrospective Cohort Study
inferred← citeshttps://doi.org/10.1001/amajethics.2020.702openalex-snapshot
Ethical Imperatives to Overcome Stigma Against People With Substance Use Disorders
inferred← citeshttps://doi.org/10.1001/amajethics.2024.551openalex-snapshot
How Should the Use of Opioids Be Regulated to Motivate Better Clinical Practice?
inferred← citeshttps://doi.org/10.1001/jama.2019.8309openalex-snapshot
Offering Emergency Buprenorphine Without a Prescription
inferred← citeshttps://doi.org/10.1001/jama.2020.22154openalex-snapshot
Changes in Outpatient Buprenorphine Dispensing During the COVID-19 Pandemic
inferred← citeshttps://doi.org/10.1001/jama.2023.1207openalex-snapshot
Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022
inferred← citeshttps://doi.org/10.1001/jamahealthforum.2022.1757openalex-snapshot
Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs
inferred← citeshttps://doi.org/10.1001/jamahealthforum.2022.1821openalex-snapshot
Trends in Buprenorphine Coverage and Prior Authorization Requirements in US Commercial Formularies, 2017-2021
inferred← citeshttps://doi.org/10.1001/jamahealthforum.2022.4001openalex-snapshot
Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care
inferred← citeshttps://doi.org/10.1001/jamahealthforum.2023.0071openalex-snapshot
State Policies Could Impede New Efforts to Increase Access to Medications for Opioid Use Disorder
inferred← citeshttps://doi.org/10.1001/jamahealthforum.2023.1982openalex-snapshot
Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines
inferred← citeshttps://doi.org/10.1001/jamahealthforum.2023.2247openalex-snapshot
Urine Drug Screening in a Telehealth Setting for the Treatment of Opioid Use Disorder
inferred← citeshttps://doi.org/10.1001/jamahealthforum.2024.2807openalex-snapshot
Disparities in Medication Use for Criminal Justice System–Referred Opioid Use Disorder Treatment
inferred← citeshttps://doi.org/10.1001/jamainternmed.2023.5701openalex-snapshot
Nurse Care Management for Opioid Use Disorder Treatment
inferred← citeshttps://doi.org/10.1001/jamainternmed.2023.6977openalex-snapshot
Medication for the Treatment of Opioid Use Disorder in Pregnancy Is Essential
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2019.20622openalex-snapshot
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.17128openalex-snapshot
High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.18223openalex-snapshot
Methadone Access for Opioid Use Disorder During the COVID-19 Pandemic Within the United States and Canada
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.23019openalex-snapshot
Polysubstance Use Among Patients Treated With Buprenorphine From a National Urine Drug Test Database
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.29409openalex-snapshot
Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.38807openalex-snapshot
Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.44955openalex-snapshot
Perspectives About Emergency Department Care Encounters Among Adults With Opioid Use Disorder
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.11634openalex-snapshot
Analysis of Stimulant Prescriptions and Drug-Related Poisoning Risk Among Persons Receiving Buprenorphine Treatment for Opioid Use Disorder
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.15287openalex-snapshot
Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014-2020
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.34168openalex-snapshot
Prescribing Characteristics Associated With Opioid Overdose Following Buprenorphine Taper
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.51856openalex-snapshot
Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.7028openalex-snapshot
Assessment of Community-Level Vulnerability and Access to Medications for Opioid Use Disorder
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.2052openalex-snapshot
Quality of Opioid Use Disorder Treatment for Persons With and Without Disabling Conditions
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.5439openalex-snapshot
Implementation Facilitation to Promote Emergency Department–Initiated Buprenorphine for Opioid Use Disorder
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.7001openalex-snapshot
Is Providing Medications for Opioid Use Disorder to Incarcerated Individuals a Cost-effective Strategy?
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2023.7036openalex-snapshot
Estimated Costs and Outcomes Associated With Use and Nonuse of Medications for Opioid Use Disorder During Incarceration and at Release in Massachusetts
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.20702openalex-snapshot
Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.21740openalex-snapshot
Medication for Opioid Use Disorder After Serious Injection-Related Infections in Massachusetts
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.2732openalex-snapshot
Prison Buprenorphine Implementation and Postrelease Opioid Use Disorder Outcomes
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.4617openalex-snapshot
Public Health Interventions and Overdose-Related Outcomes Among Persons With Opioid Use Disorder
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.47447openalex-snapshot
Nurse Care Management of Opioid Use Disorder Treatment After 3 Years
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2024.8519openalex-snapshot
Access to Mental Health and Substance Use Treatment in Comprehensive Primary Care Plus
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.1068openalex-snapshot
Hospital Security Searches Among Patients With Substance-Related Encounters
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.26077openalex-snapshot
Hospital-Based Methadone and Buprenorphine Initiation Practices by Addiction Consult Services
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2025.8469openalex-snapshot
Medicaid Unwinding and Changes in Buprenorphine Dispensing
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2026.11514openalex-snapshot
Best Practices for Hospital-Based Initiation of Medications for Opioid Use Disorder
inferred← citeshttps://doi.org/10.1001/jamapediatrics.2019.5009openalex-snapshot
Opioid Litigation and Maternal-Child Health—Investing in the Future
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2020.1511openalex-snapshot
Methadone for Opioid Use Disorder—Decades of Effectiveness but Still Miles Away in the US
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2020.1689openalex-snapshot
Predictive Modeling of Opioid Overdose Using Linked Statewide Medical and Criminal Justice Data
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2021.1969openalex-snapshot
Contingency Management for Patients Receiving Medication for Opioid Use Disorder
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2022.2284openalex-snapshot
Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic
inferred← citeshttps://doi.org/10.1001/jamapsychiatry.2022.4020openalex-snapshot
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder
inferred← citeshttps://doi.org/10.1002/emp2.12451openalex-snapshot
Advancing emergency department–initiated buprenorphine
inferred← citeshttps://doi.org/10.1002/hec.4530openalex-snapshot
How access to addictive drugs affects the supply of substance abuse treatment: Evidence from Medicare Part D
inferred← citeshttps://doi.org/10.1002/jac5.1171openalex-snapshot
Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles
inferred← citeshttps://doi.org/10.1002/jac5.1216openalex-snapshot
Meeting people where they're at: A focus on pharmacist harm reduction roles in the opioid crisis
inferred← citeshttps://doi.org/10.1002/jac5.1331openalex-snapshot
Mobilizing pharmacists to address the opioid crisis: A joint opinion of the ambulatory care and adult medicine practice and research networks of the American College of Clinical Pharmacy
inferred← citeshttps://doi.org/10.1002/jac5.1592openalex-snapshot
Call to action: Clinical pharmacy and addressing the opioid crisis
inferred← citeshttps://doi.org/10.1002/jac5.1607openalex-snapshot
Four models of pharmacist‐integrated office‐based opioid treatment
inferred← citeshttps://doi.org/10.1002/jac5.70049openalex-snapshot
Pharmacists' contributions to the management of opioid use disorder
inferred← citeshttps://doi.org/10.1002/jac5.70088openalex-snapshot
Enhancing Naloxone Distribution and Academic Detailing Effectiveness: Insights From an Online Priority Panel Report at the United States Veterans Health Administration
inferred← citeshttps://doi.org/10.1002/jcph.1937openalex-snapshot
The Epidemiology of Drug Abuse
inferred← citeshttps://doi.org/10.1002/jhm.13138openalex-snapshot
Things We Do for No Reason™: Avoiding methadone for opioid withdrawal
inferred← citeshttps://doi.org/10.1002/jhm.13146openalex-snapshot
Use of nonstigmatizing language is associated with improved outcomes in hospitalized people who inject drugs
inferred← citeshttps://doi.org/10.1002/jhm.13193openalex-snapshot
Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage
inferred← citeshttps://doi.org/10.1002/jhm.13238openalex-snapshot
Point/counterpoint: Should full agonist opioid medications be offered to hospitalized patients for management of opioid withdrawal?
inferred← citeshttps://doi.org/10.1002/jia2.70038openalex-snapshot
“From an HCV and HIV point of view, it's been remarkable”: A qualitative study about using prescribed safer supply to support people who use drugs along the HIV and HCV prevention and treatment cascades in Ontario, Canada
inferred← citeshttps://doi.org/10.1002/nur.22355openalex-snapshot
Understanding healthcare engagement for people who inject drugs
inferred← citeshttps://doi.org/10.1002/wps.21073openalex-snapshot
Substance use disorders: a comprehensive update of classification, epidemiology, neurobiology, clinical aspects, treatment and prevention
inferred← citeshttps://doi.org/10.1007/978-1-0716-1807-3_15openalex-snapshot
Screening for Public Purpose: Promoting an Evidence-Based Approach to Screening of Inmates to Improve Public Health
inferred← citeshttps://doi.org/10.1007/978-1-0716-1807-3_27openalex-snapshot
Substance Use Disorder Treatment in Correctional Facilities: Updates in Evidence-Based Treatment and Steps Forward
inferred← citeshttps://doi.org/10.1007/978-3-030-42825-9_26-1openalex-snapshot
Disorders Due to Substance Use: Stimulants
inferred← citeshttps://doi.org/10.1007/978-3-030-51366-5_26openalex-snapshot
Disorders due to Substance Use: Stimulants
inferred← citeshttps://doi.org/10.1007/978-3-030-80818-1openalex-snapshot
Treating Opioid Use Disorder in General Medical Settings
inferred← citeshttps://doi.org/10.1007/978-3-030-80818-1_12openalex-snapshot
Bringing Primary Care to Opioid Treatment Programs
inferred← citeshttps://doi.org/10.1007/978-3-030-80818-1_5openalex-snapshot
Emergency Department Treatment of Opioid Use Disorder
inferred← citeshttps://doi.org/10.1007/978-3-031-57159-6_30-1openalex-snapshot
Epidemiology and Global Impact
inferred← citeshttps://doi.org/10.1007/978-3-031-62971-6_9openalex-snapshot
Cognitive-Behavioral Therapy for Co-occurring Anxiety and Opioid Use Disorder in People with Chronic Pain
inferred← citeshttps://doi.org/10.1007/978-3-031-65179-3_13openalex-snapshot
Opioid Use Disorder in Sub-Saharan Africa: A Call for Adoption and Expansion of Harm-Reduction Programmes
inferred← citeshttps://doi.org/10.1007/s10461-021-03452-0openalex-snapshot
Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder Among Patients With and Without HIV
inferred← citeshttps://doi.org/10.1007/s10461-022-03817-zopenalex-snapshot
Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine
inferred← citeshttps://doi.org/10.1007/s10461-024-04494-wopenalex-snapshot
Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV
inferred← citeshttps://doi.org/10.1007/s10742-025-00349-6openalex-snapshot
Economic considerations of office-based methadone as an opioid use disorder treatment option: a cost-effectiveness analysis and methodological comparison
inferred← citeshttps://doi.org/10.1007/s11013-023-09842-4openalex-snapshot
The Clinical Evolutions of Surveillance and Violence During Three Contemporary US Crises: Opioid Overdose, COVID-19, and Racial Reckoning
inferred← citeshttps://doi.org/10.1007/s11414-020-09738-wopenalex-snapshot
Medicaid Expansion and Low-Income Adults with Substance Use Disorders
inferred← citeshttps://doi.org/10.1007/s11414-023-09853-4openalex-snapshot
A Cost Model for a Low-Threshold Clinic Treating Opioid Use Disorder
inferred← citeshttps://doi.org/10.1007/s11414-025-09977-9openalex-snapshot
Why All Behavioral Health Providers Need Addiction Training
inferred← citeshttps://doi.org/10.1007/s11524-026-01073-3openalex-snapshot
Housing Insecurity, Behavioral Health Disorders, and Acute Care Utilization: A Cross-Sectional Study of Medicaid Members in the Portland, Oregon Metropolitan Area
inferred← citeshttps://doi.org/10.1007/s11606-020-05815-0openalex-snapshot
Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration: a Pragmatic Retrospective Cohort Analysis
inferred← citeshttps://doi.org/10.1007/s11606-020-06257-4openalex-snapshot
Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review
inferred← citeshttps://doi.org/10.1007/s11606-020-06266-3openalex-snapshot
Expanding Access to Medications for Opioid Use Disorder: Program and Policy Approaches from Outside the Veterans Health Administration
inferred← citeshttps://doi.org/10.1007/s11606-020-06267-2openalex-snapshot
The Importance of Learning Health Systems in Addressing the Opioid Crisis
inferred← citeshttps://doi.org/10.1007/s11606-020-06295-yopenalex-snapshot
Implementation and Policy Recommendations from the VHA State-of-the-Art Conference on Strategies to Improve Opioid Safety
inferred← citeshttps://doi.org/10.1007/s11606-021-07094-9openalex-snapshot
Impact of High Deductible Health Plans on Continuous Buprenorphine Treatment for Opioid Use Disorder
inferred← citeshttps://doi.org/10.1007/s11606-021-07174-wopenalex-snapshot
Initiating Opioid Use Disorder Medication via Telemedicine During COVID-19: Implications for Proposed Reforms to the Ryan Haight Act
inferred← citeshttps://doi.org/10.1007/s11606-021-07344-wopenalex-snapshot
Mortality Among Patients Prescribed Buprenorphine for Opioid Use Disorder After Disenrollment from an Insurance Plan and Healthcare System
inferred← citeshttps://doi.org/10.1007/s11606-022-07812-xopenalex-snapshot
Availability of Medications for Opioid Use Disorder in U.S. Jails
inferred← citeshttps://doi.org/10.1007/s11606-022-07813-wopenalex-snapshot
What’s in a Name? Terminology Preferences Among Patients Receiving Methadone Treatment
inferred← citeshttps://doi.org/10.1007/s11606-023-08027-4openalex-snapshot
Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities
inferred← citeshttps://doi.org/10.1007/s11606-023-08383-1openalex-snapshot
Telehealth Initiation of Buprenorphine for Opioid Use Disorder: Patient Characteristics and Outcomes
inferred← citeshttps://doi.org/10.1007/s11606-024-08676-zopenalex-snapshot
Experiences of Aging with Opioid Use Disorder and Comorbidity in Opioid Treatment Programs: A Qualitative Analysis
inferred← citeshttps://doi.org/10.1007/s11606-024-08743-5openalex-snapshot
“It’s Like A Partnership”: Exploring the Primary Care Experiences and Patient-Defined Goals of People Who Use Drugs
inferred← citeshttps://doi.org/10.1007/s11606-024-08819-2openalex-snapshot
Association Between Cost-Sharing and Buprenorphine Prescription Abandonment
inferred← citeshttps://doi.org/10.1007/s11606-024-08837-0openalex-snapshot
Addiction Consult Service and Inpatient Outcomes Among Patients with OUD
inferred← citeshttps://doi.org/10.1007/s11606-024-08898-1openalex-snapshot
Integrating Buprenorphine for Opioid Use Disorder into Rural, Primary Care Settings
inferred← citeshttps://doi.org/10.1007/s11606-024-08916-2openalex-snapshot
Outpatient-Based Opioid Treatment Engagement and Attendance: A Prospective Cohort Study of Homeless-Experienced Adults
inferred← citeshttps://doi.org/10.1007/s11606-025-09356-2openalex-snapshot
Hepatitis C Treatment in Kentucky Medicaid Recipients with Concurrent Opioid Use Disorder: A Cross-Sectional Study
inferred← citeshttps://doi.org/10.1007/s11606-025-09820-zopenalex-snapshot
Outcomes of a Hospitalist-Led Consult Service for Patients with Opioid Use Disorder: A Propensity Score Weighted Study
inferred← citeshttps://doi.org/10.1007/s11896-023-09628-9openalex-snapshot
Police Use of Discretion in Encounters with People with Opioid Use Disorder: a Study of Illinois Police Officers
inferred← citeshttps://doi.org/10.1007/s11916-023-01185-4openalex-snapshot
Buprenorphine for Chronic Pain Management: a Narrative Review
inferred← citeshttps://doi.org/10.1007/s13181-019-00728-9openalex-snapshot
ACMT Position Statement: Remove the Waiver Requirement for Prescribing Buprenorphine for Opioid Use Disorder
inferred← citeshttps://doi.org/10.1007/s13181-021-00850-7openalex-snapshot
Descriptive Analysis of Inpatient and Outpatient Cohorts Seeking Treatment After Prescription Opioid Misuse and Medical Toxicology Evaluation
inferred← citeshttps://doi.org/10.1007/s13311-019-00814-4openalex-snapshot
Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA
inferred← citeshttps://doi.org/10.1007/s40263-020-00722-8openalex-snapshot
Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?
inferred← citeshttps://doi.org/10.1007/s40429-019-00267-xopenalex-snapshot
Treatment of Opioid Use Disorder in the Acute Hospital Setting: a Critical Review of the Literature (2014–2019)
inferred← citeshttps://doi.org/10.1007/s40429-019-00272-0openalex-snapshot
Treatment of Opioid Use Disorder in Pediatric Medical Settings
inferred← citeshttps://doi.org/10.1007/s40429-020-00350-8openalex-snapshot
Anxiety and Opioid Use Disorder: Potential Targets for Treatment and Prevention
inferred← citeshttps://doi.org/10.1007/s40429-025-00662-7openalex-snapshot
Disposition Factors Impacting Buprenorphine Salivary Gland Accumulation and Oral Fluid Exposure
inferred← citeshttps://doi.org/10.1007/s40501-020-00218-8openalex-snapshot
Integrating Evidence-Based Guidelines on Pain and Opioids into Medical School Education
inferred← citeshttps://doi.org/10.1016/b978-0-12-820237-1.00022-3openalex-snapshot
Cognitive behavioral therapy for chronic pain and opioid use disorder
inferred← citeshttps://doi.org/10.1016/b978-0-323-68328-9.00004-7openalex-snapshot
Opioid use disorder, infectious diseases, and the criminal justice system
inferred← citeshttps://doi.org/10.1016/bs.vh.2024.10.004openalex-snapshot
Opioid reward and deep brain stimulation of the lateral hypothalamic area
inferred← citeshttps://doi.org/10.1016/j.abrep.2019.100212openalex-snapshot
Psychiatric symptoms and recent overdose among people who use heroin or other opioids: Results from a secondary analysis of an intervention study
inferred← citeshttps://doi.org/10.1016/j.abrep.2025.100588openalex-snapshot
Association between different modalities of opioid use disorder-related care delivery and opioid use disorder-related patient outcomes: A retrospective cohort study
inferred← citeshttps://doi.org/10.1016/j.acap.2024.06.007openalex-snapshot
Pediatric Primary Care of Children With Intrauterine Opioid Exposure: Survey of Academic Teaching Practices
inferred← citeshttps://doi.org/10.1016/j.addbeh.2021.107113openalex-snapshot
Systematic review and meta-analysis of retention in treatment using medications for opioid use disorder by medication, race/ethnicity, and gender in the United States
inferred← citeshttps://doi.org/10.1016/j.ajem.2023.01.009openalex-snapshot
Variability in opioid use disorder clinical presentations and treatment in the emergency department: A mixed-methods study
inferred← citeshttps://doi.org/10.1016/j.amepre.2020.08.017openalex-snapshot
Data Needs in Opioid Systems Modeling: Challenges and Future Directions
inferred← citeshttps://doi.org/10.1016/j.annemergmed.2021.03.023openalex-snapshot
Improve Access to Care for Opioid Use Disorder: A Call to Eliminate the X-Waiver Requirement Now
inferred← citeshttps://doi.org/10.1016/j.annemergmed.2021.04.023openalex-snapshot
Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department
inferred← citeshttps://doi.org/10.1016/j.bpsgos.2021.04.009openalex-snapshot
Opioid Withdrawal Produces Sex-Specific Effects on Fentanyl-Versus-Food Choice and Mesolimbic Transcription
inferred← citeshttps://doi.org/10.1016/j.cct.2023.107124openalex-snapshot
A Patient-Centered Nurse-Supported Primary Care-Based Collaborative Care Program to Treat Opioid Use Disorder and Depression; Design and Protocol for the MI-CARE Randomized Controlled Trial
inferred← citeshttps://doi.org/10.1016/j.clinthera.2019.07.019openalex-snapshot
Personal and Socioeconomic Determinants in Medication-assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults
inferred← citeshttps://doi.org/10.1016/j.dadr.2022.100084openalex-snapshot
Under-representation of key demographic groups in opioid use disorder trials
inferred← citeshttps://doi.org/10.1016/j.dadr.2022.100106openalex-snapshot
Hospitalist perspectives on buprenorphine treatment for inpatients with opioid use disorder
inferred← citeshttps://doi.org/10.1016/j.dadr.2023.100135openalex-snapshot
Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design
inferred← citeshttps://doi.org/10.1016/j.dadr.2023.100138openalex-snapshot
Experiences of healthcare and substance use treatment provider-based stigma among patients receiving methadone
inferred← citeshttps://doi.org/10.1016/j.dadr.2024.100226openalex-snapshot
Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder
inferred← citeshttps://doi.org/10.1016/j.dadr.2024.100235openalex-snapshot
The effect of a pilot brief educational intervention on preferences regarding treatments for opioid use disorder
inferred← citeshttps://doi.org/10.1016/j.dadr.2024.100292openalex-snapshot
Prevalence, patterns, and predictors of prescribing medications for opioid use disorder (MOUD) in the Inpatient setting
inferred← citeshttps://doi.org/10.1016/j.dadr.2024.100299openalex-snapshot
The power of lived experience in optimizing US policymakers’ engagement with substance use research: A series of rapid-cycle randomized controlled trials
inferred← citeshttps://doi.org/10.1016/j.dadr.2024.100311openalex-snapshot
Receipt of medications for opioid use disorder among rural and urban veterans health administration patients
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2019.107563openalex-snapshot
Evidence for state, community and systems-level prevention strategies to address the opioid crisis
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2019.107654openalex-snapshot
State criminal justice policy context and opioid agonist treatment delivery among opioid treatment admissions, 2015
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2020.107858openalex-snapshot
Estimating the impact of wide scale uptake of screening and medications for opioid use disorder in US prisons and jails
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2020.107968openalex-snapshot
Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2020.108067openalex-snapshot
The effect of medications for opioid use disorder (MOUD) on residential treatment completion and retention in the US
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2020.108217openalex-snapshot
Comparing perspectives on medication treatment for opioid use disorder between national samples of primary care trainee physicians and attending physicians
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2020.108253openalex-snapshot
Successful engagement in buprenorphine treatment among hospitalized patients with opioid use disorder and trauma
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2020.108317openalex-snapshot
Adherence to buprenorphine: An analysis of prescription drug monitoring program data
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2020.108325openalex-snapshot
The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2020.108330openalex-snapshot
Model and approach for assessing implementation context and fidelity in the HEALing Communities Study
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2020.108387openalex-snapshot
Alexithymia and pain experience among patients using methadone-maintenance therapy
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2020.108435openalex-snapshot
Predictors of enrollment in opioid agonist therapy after opioid overdose or diagnosis with opioid use disorder: A cohort study
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2020.108501openalex-snapshot
Implications of county-level variation in U.S. opioid distribution
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108512openalex-snapshot
Medications for opioid use disorder among American Indians and Alaska natives: Availability and use across a national sample
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108534openalex-snapshot
Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108627openalex-snapshot
The role of stigma in U.S. primary care physicians’ treatment of opioid use disorder
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108644openalex-snapshot
Letter to the Editor regarding: Buprenorphine for opioid use disorder: The role of public funding in its development (by Barenie and Kesselheim, 2020)
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108646openalex-snapshot
A randomized controlled trial of a brief behavioral intervention to reduce skin and soft tissue infections among people who inject drugs
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108661openalex-snapshot
Quantifying opioid use disorder Cascade of Care outcomes in an American Indian tribal nation in Minnesota
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108703openalex-snapshot
Shorter outpatient wait-times for buprenorphine are associated with linkage to care post-hospital discharge
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108729openalex-snapshot
Pharmacy-related buprenorphine access barriers: An audit of pharmacies in counties with a high opioid overdose burden
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108764openalex-snapshot
Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108784openalex-snapshot
Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder?
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108799openalex-snapshot
Characterizing opioid agonist treatment discontinuation trends in British Columbia, Canada, 2012–2018
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108811openalex-snapshot
Primary care physicians’ preparedness to treat opioid use disorder in the United States: A cross-sectional survey
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108849openalex-snapshot
Racial/ethnic disparities in the use of medications for opioid use disorder (MOUD) and their effects on residential drug treatment outcomes in the US
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108881openalex-snapshot
Structural and organizational factors shaping access to medication treatment for opioid use disorder in community supervision
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108890openalex-snapshot
Predictors of enrollment in opioid agonist therapy after opioid overdose or diagnosis with opioid use disorder: A cohort study
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108923openalex-snapshot
Adjunct interventions to standard medical management of buprenorphine in outpatient settings: A systematic review of the evidence
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108927openalex-snapshot
Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2021.108937openalex-snapshot
Post-incarceration outcomes for individuals who continued methadone treatment while in Connecticut jails, 2014–2018
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2022.109325openalex-snapshot
“It’s probably going to save my life;” attitudes towards treatment among people incarcerated in the era of fentanyl
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2022.109340openalex-snapshot
Medicaid expansion and drug overdose mortality during the COVID-19 pandemic in the United States
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2022.109495openalex-snapshot
County-level sociodemographic differences in availability of two medications for opioid use disorder: United States, 2019
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2022.109497openalex-snapshot
Bridge clinic implementation of “72-hour rule” methadone for opioid withdrawal management: Impact on opioid treatment program linkage and retention in care
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2022.109498openalex-snapshot
Treatment outcomes associated with medications for opioid use disorder (MOUD) among criminal justice-referred admissions to residential treatment in the U.S., 2015–2018
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2022.109507openalex-snapshot
Identifying key risk factors for premature discontinuation of opioid use disorder treatment in the United States: A predictive modeling study
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2022.109609openalex-snapshot
Buprenorphine & methadone dosing strategies to reduce risk of relapse in the treatment of opioid use disorder
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2022.109669openalex-snapshot
Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2023.110940openalex-snapshot
Racial inequities and addiction research
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2023.111014openalex-snapshot
Drug overdose mortality rates by educational attainment and sex for adults aged 25–64 in the United States before and during the COVID-19 pandemic, 2015–2021
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2023.111025openalex-snapshot
Racialized and beneficiary inequities in medication to treat opioid use disorder receipt within the US Military Health System
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2023.111040openalex-snapshot
Receipt of opioid use disorder treatments prior to fatal overdoses and comparison to no treatment in Connecticut, 2016–17
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2024.111252openalex-snapshot
Nine-year substance use treatment outcomes with buprenorphine for opioid use disorder in a federally qualified health center
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2024.111274openalex-snapshot
Impact of jail-based methadone or buprenorphine treatment on non-fatal opioid overdose after incarceration
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2024.111281openalex-snapshot
Association of buprenorphine retention and subsequent adverse outcomes following non-fatal overdose: An analysis using statewide linked Maryland databases
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2024.111350openalex-snapshot
Offering nurse care management for opioid use disorder in primary care: Impact on emergency and hospital utilization in a cluster-randomized implementation trial
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2024.111377openalex-snapshot
Transitions of care between jail-based medications for opioid use disorder and ongoing treatment in the community: A retrospective cohort study
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2024.111392openalex-snapshot
Receipt of medications for opioid use disorder before and after incarceration in Massachusetts State prisons, 2014-2019
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2024.112432openalex-snapshot
Examining the effect of prescription drug monitoring program integration and mandatory use policies on the distribution of methadone and buprenorphine for opioid use disorder, United States, 2009–2021
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2024.112448openalex-snapshot
Community-based medical education in addiction and harm reduction: Perspectives on addiction medicine training
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2024.112456openalex-snapshot
Buprenorphine use among non-hospital residential programs
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2025.112586openalex-snapshot
Real-world access to buprenorphine treatment in Philadelphia: A secret shopper study
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2025.112598openalex-snapshot
Buprenorphine adherence among a prospective cohort of homeless-experienced adults with opioid use disorder
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2025.112628openalex-snapshot
The opioid epidemic in rural communities: Can telehealth increase access to medications for opioid use disorder and offset barriers to care?
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2025.112742openalex-snapshot
Predictors of Medicaid managed care plan performance on opioid use disorder treatment quality metrics
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2025.112775openalex-snapshot
Treatment initiations and opioid overdoses among recently incarcerated people after adoption of the take-home methadone policy
inferred← citeshttps://doi.org/10.1016/j.drugalcdep.2025.112914openalex-snapshot
Implementation opportunities for optimizing retention on buprenorphine treatment for people with opioid use disorder in West Virginia
inferred← citeshttps://doi.org/10.1016/j.drugpo.2019.09.008openalex-snapshot
Barriers to naloxone use and acceptance among opioid users, first responders, and emergency department providers in New Hampshire, USA
inferred← citeshttps://doi.org/10.1016/j.drugpo.2020.102841openalex-snapshot
Optimizing the impact of medications for opioid use disorder at release from prison and jail settings: A microsimulation modeling study
inferred← citeshttps://doi.org/10.1016/j.drugpo.2021.103140openalex-snapshot
“How will I get my next week's script?” Reactions of Reddit opioid forum users to changes in treatment access in the early months of the coronavirus pandemic
showing the first 200 of 712
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.